Last updated: September 8, 2026
Sogroya, Novo Nordisk’s once-weekly human growth hormone, is expanding within a global growth hormone market that remains dominated by daily somatropin products. The drug generated approximately DKK 2.1 billion in 2024 sales, up from about DKK 1.4 billion in 2023. Growth is being driven by pediatric expansion, adult growth hormone deficiency, weekly dosing convenience, and Novo Nordisk’s established endocrinology infrastructure.[1]
Sogroya’s commercial opportunity is substantial, but competition is intensifying. Pfizer’s Skytrofa, Ascendis Pharma’s long-acting growth hormone, and Pfizer’s Ngenla are competing for the same shift from daily injections to longer-acting treatment. Sogroya’s U.S. biologic exclusivity runs from its first approval in August 2020, with the statutory 12-year period extending into 2032. Patent rights and regulatory exclusivity could protect the product beyond that date, although the commercial outcome will depend on patent scope, biosimilar development, reimbursement, and physician adoption.
How much revenue does Sogroya generate?
Sogroya sales increased rapidly from launch, with reported growth remaining well above the broader mature growth hormone market.
| Fiscal year |
Sogroya sales |
Approximate year-over-year growth |
| 2020 |
DKK 66 million |
Launch year |
| 2021 |
DKK 398 million |
503% |
| 2022 |
DKK 992 million |
149% |
| 2023 |
DKK 1.4 billion |
42% |
| 2024 |
DKK 2.1 billion |
49% |
Source: Novo Nordisk annual reports and company financial disclosures.[1]
From 2020 to 2024, reported sales increased at an approximate compound annual growth rate of 135%, although the calculation is distorted by the low launch-year base. From 2023 to 2024, sales rose by roughly DKK 700 million.
Sogroya remains a small product within Novo Nordisk’s total portfolio, which is dominated by GLP-1 and insulin products. Its strategic value is different from its absolute revenue contribution. The product gives Novo Nordisk exposure to a specialty biologic market with recurring treatment, strong prescriber concentration, and a long commercial runway.
What is Sogroya’s revenue exposure by market?
Novo Nordisk reports Sogroya sales at the global product level rather than consistently providing a detailed country-by-country revenue breakdown. The United States is commercially important because it has:
- A large diagnosed adult growth hormone deficiency population.
- High specialty-drug reimbursement levels.
- Broad adoption of self-injection therapies.
- A mature endocrinology distribution network.
- Significant commercial value for weekly dosing.
International markets contribute through both adult and pediatric indications. Market access varies substantially because growth hormone reimbursement is often subject to age, diagnosis, prior authorization, treatment response, and national budget rules.
What is driving Sogroya market growth?
Sogroya’s growth is based on product differentiation and market conversion rather than a new therapeutic mechanism.
Once-weekly administration
Sogroya contains somapacitan-beco, a long-acting recombinant human growth hormone derivative designed for once-weekly subcutaneous administration. Traditional somatropin products generally require daily injections. Reducing injection frequency can improve treatment convenience and may support persistence, although real-world adherence advantages vary by patient and caregiver.
The product competes on dosing frequency, device usability, treatment flexibility, and reimbursement. Clinical efficacy remains important, but weekly administration is the central commercial proposition.
Expansion into pediatric growth hormone deficiency
The FDA approved Sogroya for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone in April 2023. The original U.S. approval in August 2020 covered adults with growth hormone deficiency.[2]
Pediatric approval materially expanded the addressable population. Children generally represent a larger treatment pool than adults, although pediatric access is highly dependent on insurance coverage, specialist diagnosis, growth monitoring, and treatment duration.
The pediatric market is also more competitive. Daily products have extensive clinical history, while long-acting competitors are seeking to establish comparable growth outcomes and convenience.
Adult replacement therapy
Adult growth hormone deficiency is a smaller population than pediatric deficiency but can have attractive commercial characteristics. Adult patients often receive long-term replacement therapy, and weekly dosing can reduce injection burden. Adult prescribing is affected by diagnostic testing, contraindications, payer restrictions, and endocrinologist preference.
Sogroya’s adult indication was important for establishing the product before the pediatric label expansion. It also gave Novo Nordisk experience with reimbursement and patient-support programs before entering the larger pediatric segment.
How does Sogroya compare with competing growth hormone products?
Sogroya competes against daily somatropin and other long-acting growth hormone products.
| Product |
Active ingredient |
Dosing profile |
Company |
Competitive position |
| Sogroya |
Somapacitan-beco |
Once weekly |
Novo Nordisk |
Adult and pediatric growth hormone deficiency |
| Skytrofa |
Lonapegsomatropin-tcgd |
Once weekly |
Ascendis Pharma |
Pediatric and adult growth hormone deficiency |
| Ngenla |
Somatrogon-ghla |
Once weekly |
Pfizer |
Pediatric growth hormone deficiency |
| Norditropin |
Somatropin |
Daily |
Novo Nordisk |
Established daily growth hormone franchise |
| Genotropin |
Somatropin |
Daily |
Pfizer |
Established daily growth hormone franchise |
| Omnitrope |
Somatropin |
Daily |
Sandoz |
Biosimilar/recombinant somatropin competitor |
| Humatrope |
Somatropin |
Daily |
Eli Lilly |
Established daily growth hormone product |
The competitive distinction is shifting from daily versus weekly dosing to weekly product performance, device experience, safety, reimbursement, and supply reliability. Long-acting products may face less substitution based solely on price because treatment decisions are specialist-driven and often involve patient support.
Skytrofa is the most direct commercial comparison because it also targets weekly administration and has an established pediatric presence. Ngenla increases competitive pressure in pediatric endocrinology. Novo Nordisk’s advantage is its global commercial scale, established Norditropin relationships, and ability to use existing endocrinology infrastructure.
What is Sogroya’s FDA regulatory status?
Sogroya is approved in the United States as a biologic under a Biologics License Application. The FDA approved the product for:
- Adults with growth hormone deficiency in August 2020.
- Children aged 2.5 years and older with growth failure due to inadequate secretion of endogenous growth hormone in April 2023.[2]
Sogroya is also marketed in multiple international jurisdictions, including Europe, where somapacitan has been authorized for growth hormone deficiency in adults and children under specified label conditions.[3]
The product is not an ordinary small-molecule drug. A future competitor would generally pursue a biosimilar pathway under Section 351(k) of the Public Health Service Act rather than an ANDA pathway under the Hatch-Waxman Act.
When does Sogroya lose regulatory exclusivity?
Sogroya received first licensure as a biologic in August 2020. The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity from first licensure. On that basis, the principal U.S. biologic exclusivity period extends to approximately August 2032.[4]
If applicable pediatric exclusivity is granted, the period could be extended by six months. The statutory framework does not eliminate separate patent disputes, patent settlements, or regulatory barriers affecting a biosimilar launch.
| Exclusivity category |
Relevant timing |
| First U.S. approval |
August 2020 |
| Standard BPCIA reference-product exclusivity |
Approximately August 2032 |
| Potential pediatric extension |
Up to six additional months |
| Earliest routine biosimilar development |
Before exclusivity expiry, subject to applicable rules |
| Commercial biosimilar launch |
Dependent on exclusivity, patents, litigation, and settlement terms |
What patents protect Sogroya?
Sogroya is protected by a portfolio covering the modified growth hormone molecule, formulations, manufacturing processes, dosing, and potentially delivery or treatment methods. Novo Nordisk has historically used layered patenting for peptide and biologic products rather than relying on a single composition-of-matter patent.
The relevant patent categories are:
Somapacitan molecule patents
These claims cover the long-acting growth hormone construct and its chemical or structural components. Composition-related claims generally provide the strongest protection because they can block competing products that use the same active molecule.
Formulation patents
Formulation claims may cover stability, concentration, excipients, storage conditions, and injectable presentations. These rights can complicate biosimilar development but are less powerful than a valid composition claim if a competitor can design around the formulation.
Method-of-use patents
Sogroya’s label-specific treatment claims may cover weekly administration, patient populations, dosing regimens, or treatment of growth hormone deficiency. Method-of-use patents can create litigation risk where a biosimilar seeks a partial label or uses a skinny-label strategy.
Manufacturing patents
Manufacturing claims may cover production of the modified protein, conjugation chemistry, purification, or process controls. These rights can increase development costs and create trade-secret exposure, but they do not necessarily prevent a biosimilar manufacturer from using a different process.
Public patent databases and FDA records should be reviewed separately for the current U.S. patent family, terminal disclaimers, PTA, PTE, Orange Book listings, and any BPCIA patent-exchange activity. Biologic products do not use the Orange Book in the same manner as small-molecule drugs. Their core exclusivity and patent information is assessed through biologic-license records, patent databases, FDA reference-product data, and litigation filings.
Does Sogroya have Orange Book protection?
Sogroya is a biologic, not a conventional small-molecule product approved through an NDA. The Orange Book is therefore not the primary source for its exclusivity analysis.
The more relevant questions are:
- Whether a follow-on product qualifies as a biosimilar or interchangeable biosimilar.
- Whether the reference-product exclusivity period has expired.
- Which patents are identified during the BPCIA patent dance.
- Whether Novo Nordisk files an infringement action.
- Whether the parties reach a settlement governing launch timing.
An absence of conventional Orange Book listing should not be interpreted as an absence of patent protection.
Are there Paragraph IV challenges to Sogroya?
A standard Paragraph IV ANDA challenge is not the expected pathway for Sogroya because Sogroya is a biologic. A competing manufacturer would generally use the 351(k) biosimilar pathway and could contest patents through the BPCIA process.
Through the public record available through 2024, Sogroya had not generated a widely reported public biosimilar patent litigation campaign comparable to major small-molecule products. That does not remove future litigation risk. A biosimilar developer could begin analytical and clinical development years before the expected 2032 loss of reference-product exclusivity.
What biosimilar risks exist for Sogroya?
Biosimilar risk is likely to develop gradually because somapacitan is a structurally modified protein rather than an unmodified daily somatropin product. A biosimilar developer would need to demonstrate high similarity in analytical characteristics, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical performance.
The principal barriers are:
- Complex characterization of the modified molecule.
- Manufacturing and conjugation process control.
- Long-term pediatric safety requirements.
- Immunogenicity assessment.
- Device and delivery-system comparability.
- Specialist and payer acceptance.
- Patent litigation and settlement timing.
A biosimilar may not need to replicate every aspect of the reference product’s manufacturing process. It would need to meet FDA similarity requirements and address patent claims that cover the molecule, formulation, or use.
What generic launch scenarios are likely for Sogroya?
Sogroya is unlikely to face a conventional generic launch. The realistic scenarios are:
Early biosimilar entry through settlement
Novo Nordisk could resolve patent disputes through an agreement allowing entry before full patent expiry. Launch timing would depend on the negotiated date and any regulatory exclusivity remaining.
Entry after biologic exclusivity
A biosimilar could launch after the August 2032 reference-product exclusivity period, subject to patent validity and enforceability.
Delayed entry from manufacturing complexity
Even after legal barriers expire, development, manufacturing scale-up, regulatory review, and payer contracting could delay commercial entry.
Limited-label biosimilar entry
A competitor could seek approval for a narrower indication if certain method-of-use patents remain enforceable. Commercial uptake would depend on whether physicians and payers consider the narrower label sufficient.
How strong is the Sogroya patent estate?
Sogroya’s patent estate is commercially meaningful because it combines a differentiated biologic molecule with formulation, method-of-use, and manufacturing protection. The strongest protection is likely to come from valid claims directed to the somapacitan structure and its long-acting configuration.
The estate has limits. Biologic patents can be challenged on written description, enablement, obviousness, anticipation, claim construction, and patent-term grounds. Method and formulation claims are more vulnerable to design-around strategies than composition claims. The ultimate protection period depends on issued claims, patent-term adjustment, patent-term extension, terminal disclaimers, and litigation outcomes.
Overall, Sogroya has a stronger commercial position than a mature daily somatropin product facing ordinary biosimilar substitution, but its long-term protection will not depend on patents alone. Novo Nordisk must preserve physician preference, reimbursement, supply reliability, and pediatric growth outcomes.
What licensing deals affect Sogroya?
Sogroya is primarily an internally developed and commercialized Novo Nordisk product. No major third-party licensing transaction has been publicly identified as a central driver of Sogroya’s commercial strategy through 2024.
Its commercial model relies on Novo Nordisk’s own:
- Discovery and biologics platform.
- Manufacturing network.
- Endocrinology sales force.
- Patient-support infrastructure.
- International regulatory organization.
That structure gives Novo Nordisk greater control over pricing and supply, while leaving the company responsible for the full cost of clinical development and commercialization.
What is the financial outlook for Sogroya?
Sogroya’s near-term outlook remains positive because pediatric approval expanded the addressable population and weekly growth hormone is still gaining market attention. Continued sales growth will depend on conversion from daily somatropin, reimbursement, competitive weekly products, and the ability to maintain premium pricing.
Key commercial variables include:
| Driver |
Likely effect |
| Pediatric adoption |
Expands patient pool and treatment duration |
| Adult weekly dosing |
Supports recurring replacement therapy |
| Skytrofa and Ngenla |
Increases pricing and formulary pressure |
| Daily somatropin franchises |
Limits rapid conversion |
| Biosimilar development |
Creates longer-term price risk |
| Novo Nordisk distribution |
Supports specialist reach and patient access |
| Manufacturing scale |
Can protect supply and gross margin |
| Payer restrictions |
Can slow patient starts and switching |
Sogroya is unlikely to reach the revenue scale of Novo Nordisk’s diabetes and obesity franchises. It can, however, become a durable specialty product with multi-billion-kroner annual sales, especially if weekly therapy becomes the preferred standard for newly diagnosed pediatric and adult patients.
Key Takeaways
- Sogroya sales reached approximately DKK 2.1 billion in 2024, up from DKK 1.4 billion in 2023.
- The main growth drivers are once-weekly dosing, pediatric approval, and Novo Nordisk’s endocrinology commercial platform.
- Sogroya competes directly with Skytrofa and Ngenla, while daily somatropin products remain important substitutes.
- U.S. BPCIA reference-product exclusivity runs from August 2020 to approximately August 2032.
- Sogroya is subject to biologic and patent analysis rather than a conventional generic and Orange Book framework.
- Future biosimilar risk will depend on molecule complexity, patent scope, manufacturing capability, and settlement timing.
- Novo Nordisk’s patent estate is likely to include molecule, formulation, method-of-use, and manufacturing rights.
- The product’s financial trajectory is positive, but pricing pressure should rise as weekly competitors mature.
Frequently Asked Questions
Is Sogroya a biosimilar?
No. Sogroya is an original biologic product containing somapacitan-beco, a long-acting growth hormone derivative. Future competitors would generally seek approval as biosimilars.
Is Sogroya more expensive than daily growth hormone?
Sogroya can carry a premium because it is a long-acting biologic with once-weekly administration. Net pricing depends on payer contracts, rebates, patient assistance, and country-specific reimbursement.
Can Sogroya be used in children?
Yes. The FDA approved Sogroya for children aged 2.5 years and older with growth failure caused by inadequate secretion of endogenous growth hormone.[2]
What is the biggest competitive threat to Sogroya?
The most direct threats are other weekly products, particularly Skytrofa and Ngenla. Daily somatropin remains a major competitor because of its long clinical history, broad availability, and established reimbursement.
Will Sogroya face a generic launch in 2032?
A conventional generic launch is unlikely. The relevant risk is a 351(k) biosimilar launch after reference-product exclusivity and any enforceable patent barriers expire.
References
-
Novo Nordisk A/S. (2021-2025). Annual reports and financial results. Novo Nordisk.
-
U.S. Food and Drug Administration. (2020, August 28). FDA approves first once-weekly treatment for adults with growth hormone deficiency. FDA.
-
European Medicines Agency. (2021). Sogroya: EPAR product information. EMA.
-
U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products under the Biologics Price Competition and Innovation Act. FDA.
